Patients with a high tumor expression of CEA have a worse prognosis than those with tumors with a negative/low expression of this marker (median OS 7.2 vs. 10.6 months, p = 0.0157; HR = 1.38, 95% confidence interval (CI) = 1.078–1.786, p = 0.0123) (Figure 3B,C). The gene discussed is CEACAM5; the disease is neoplasm.